TelesisBio



Management Presentation

Telesis Bio | Q2 2025

Safe Harbor Statement

The information contained in this presentation has been made available to you with the consent of Telesis Bio Inc. (“Telesis Bio,” the “Company,” “we” or “our”) for informational purposes only. This presentation is strictly confidential and may not be reproduced or redistributed in whole or in part nor may its contents be disclosed to any other person without our prior written permission. By viewing this presentation, you agree to keep any information (including oral information) that we provide as part of the presentation confidential and not to disclose any of the information to any other person without such permission.

This presentation contains forward-looking statements. All statements contained in this presentation other than statements of historical facts, including our business strategy and plans and objectives for future operations, including our financial performance, are forward-looking statements. The words “anticipate,” “believe,” "continue," "estimate," "expect," "intend," "may," “designed to,” “will” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Forward-looking statements made in this presentation include statements about estimates of the synthetic biology market, market growth, and new market expansion; our future revenue, expenses, capital requirements and our needs for additional financing; our expectations regarding the rate and degree of market acceptance of our BioXp system, BioXp kits and benchtop reagents; the ability of our products to facilitate the design-build-test paradigm of synthetic biology; and the size and growth of the synthetic biology market and competitive companies and technologies and our industry, and many others. Forward-looking statements are subject to a number of risks and uncertainties and represent our views as of the date of the presentation. The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We describe these and other risks and uncertainties in our filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC website. You should not rely on these statements as representing our views in the future. The forward-looking statements contained in this presentation speak only as of the date of this presentations and we undertake no obligation or duty to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation is not an offer to sell securities of Telesis Bio and it is not soliciting offers to buy securities of Telesis Bio in any jurisdiction where the offer or sale is not permitted.

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that these third-party sources and estimates are reliable, but have not independently verified them. Our estimates of the potential market opportunities for our products include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a
small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by us.

Trademarks in this presentation are the property of their respective owners and used for informational and education purposes only.

TelesisBio

Leveraging deep market expertise and groundbreaking technology to deliver on-demand synthetic biology solutions that accelerate discovery

Gibson SOLA for overnight synthesis of DNA and RNA

Leadership Team of Domain Experts

Eric Esser
President & CEO

Rocky McDonald
VP of Finance

Daniel Gibson
Chief Technology Officer

Michael Nemzek
Chief Commercial Officer

Krishna Kannan
VP, Operations and Product

Transforming the Business

Groundbreaking Next-gen Technology

Gibson SOLA reagent and software solution for on-demand DNA and RNA synthesis



Shaping the company to maximize efficiency and capture value

New product offering optimized for market fit

Path to profitability within one year

Outsourced Synthesis Slows and Constrains Therapeutic Discovery



Unpredictable Timing

Variable lead times and extended time to results

Inconsistent Quality

Variable purity and fidelity make results unpredictable



Complexity Limits

Researchers are often forced to modify designs or use multiple specialized vendors to accommodate high complexities

Valuable IP Is Exposed

Proprietary data must be shared off-premise, and data insights are kept by the service provider instead of feeding internal AI models

Gibson SOLA Synthesis Puts Control Back into the Hands of Researchers

Comprehensive and flexible reagent and software solution for on-demand synthesis to accelerate discovery

- Unlock the power of overnight synthesis of DNA, RNA and protein
- Extreme quality, high reliability, and fully automated on your platform of choice
- Complex design options to power therapeutic discovery
- Rich data stays in-house to advance AI/ML discovery pipelines



High Value Applications

Telesis Bio's Gibson SOLA synthesis solution advances and accelerates discovery across a wide range of applications at the leading edge of life science

Antibody Discovery

Cell and Gene Therapies

mRNA Vaccine Discovery

Rapid Molecular Diagnostics

Telesis Bio Is Built on a History of Innovation in Molecular Biology

JCVI
J. CRAIG VENTER INSTITUTE®

Original IP from JCVI

00 → A
01 → G
10 → C
11 → T

Digital to Biological Conversion



Gibson Short Oligonucleotide Ligation Assembly (SOLA)

Gibson Assembly

Telesis Bio Established

TelesisBio

330+

patents in Telesis patent portfolio



30,000+

citations from 30+ publications

Gibson SOLA is a Novel Approach that is Superior to Traditional Methods

Chemical or Enzymatic



1 base a time **Synthesis**

- ☒ Highly constrained construct length and complexity
- ☒ Inherently low fidelity and purity
- ☒ Toxic waste (phosphoramidite)
- ☒ Not scalable without massive infrastructure

Gibson SOLA



Block approach **Assembly**

- ☑ Easy to scale with standard liquid handling automation
- ☑ Amenable to very high throughput applications
- ☑ Simple, reliable, and fast ligation approach enables very long constructs with extreme fidelity and purity
- ☑ Comprehensive and flexible software solution enables high complexity and ease of use

Multiple Adoption Paths to Fit a Wide Array of Needs



Gibson SOLA

GIBSON SOLA FOR BECKMAN

Robust Throughput

DNA
mRNA*
Protein*

Overnight

GIBSON SOLA CUSTOM IMPLEMENTATION



Very High Throughput

DNA
mRNA
Protein
Any Endpoint

Overnight

TELESIS BIO BIOXP®

Low Throughput

DNA
mRNA

7days

*Coming soon in a future update

Beckman Coulter Development Collaboration Will Accelerate Adoption and Drive Value

Large installed base can easily adopt Gibson SOLA and immediately gain the advantages of overnight on-demand synthesis

Gibson SOLA for Beckman

- Ready to use reagent kits
- Software for design and synthesis control



Hardware

- Defined Beckman Echo / Biomek i7 configuration

The Synthetic DNA and mRNA Market is Large and Growing

$5.8B

GROWING AT 19%*



*DNA Synthesis Market Report, Global Market Insights, 2024

Gibson SOLA Unlocks Tremendous Value by Accelerating Time To Market

Pfizer

2-year Research Program



$18M

Potential Commercial Milestones

$480M+

Solid Unit Economics to Support Profitable Growth

Gibson SOLA generates revenue through reagent kits and software licensing



Competitive Pricing

$0.20

per base at volume



Durable Recurring Income

$100-500K+

per year per customer

Attractive Margins

70-80%

Advancements of Gibson SOLA Broadens Customer Base



Innovating Solutions to Rapidly Advance Therapeutic and Diagnostic Development



Gibson SOLA - Groundbreaking next-gen technology



Meeting market needs – overnight results, complexity, control

Experienced team with market expertise

Targeting high value applications



Nimble company focused on efficiency and value

Thank You

CONTACT

Rocky McDonald, VP of Finance
Rocky.McDonald@telesisbio.com
(619) 518-9270

TelesisBio